Understand the source comparison
AOD-9604 Dosing and Storage: Research Protocol Comparison
Daily Dose 300mcg subcutaneous 500mcg split twice daily Same dose, degraded peptide 300mcg is the evidence-supported starting dose; higher doses in published trials (up to 1mg) showed no additional lipolytic benefit and increased injection-site reactions Injec
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Daily Dose
- 300mcg subcutaneous
- 500mcg split twice daily
- Same dose, degraded peptide
- 300mcg is the evidence-supported starting dose; higher doses in published trials (up to 1mg) showed no additional lipolytic benefit and increased injection-site reactions
- Injection Timing
- Fasted state, 30–60min pre-cardio
- Morning + evening split dose
- Timing irrelevant if peptide denatured
- Fasted-state dosing leverages endogenous catecholamine synergy. Fed-state injection reduces efficacy by 40–60% due to insulin antagonism
- Reconstituted Stability
- 28 days at 2–8°C
- 14 days if stored above 8°C
- 48–72 hours at room temp before full degradation
- Bacteriostatic water prevents bacterial growth but does NOT prevent thermal degradation. Peptide bonds break at temps above 25°C
- Frequency
- 5 days/week (M-F dosing common)
- 7 days/week continuous
- Inconsistent due to supply interruption
- 5-day schedules prevent receptor desensitization while maintaining therapeutic levels; 2-day breaks don't significantly drop plasma concentration given 8-hour half-life
- Duration
- 12–16 weeks
- 24+ weeks in observational studies
- Protocol ends prematurely
- 12-week minimum needed to assess sustained fat loss; longer durations show continued effect without tachyphylaxis in Monash trials